[1] Osborn M. Safety and efficacy of entecavir for the treatment of chronic hepatitis B. Infect Drug Resist,2011,4:55-64. [2] 中华医学会肝病学分会和感染病学分会. 慢性乙型肝炎防治指南(2010年版). 实用肝脏病杂志,2011,14(2):81-89. [3] Head KA. Peripheral neuropathy:pathogenic mechanisms and alternative therapies. Altern Med Rev,2006,11(4):294-329. [4] Azhary H,Farooq MU,Bhanushali M,et al. Peripheral neuropathy:differential diagnosis and management. Am Fam Physic,2010,81(7):887-892. [5] Fung L,Seto WK,Lai CL,et al. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. J Gastroenterol Hepatol,2014,29(3):428-434. [6] Fodale V,Mazzeo A,Praticò C,et al. Fatal exacerbation of peripheral neuropathy during lamivudine therapy:evidence for iatrogenic mitochondrial damage. Anaesthesia,2005,60(8): 806-810. [7] Xu H,Wang Z,Zheng L,et al. Lamivudine/telbivudine-associated neuromyopathy:neurogenic damage,mitochondrial dysfunction and mitochondrial DNA depletion. J Clin Pathol,2014,67(11): 999-1005. [8] 张晓红,吴元凯,曹红,等. 恩替卡韦治疗乙型肝炎肝硬化并发周围神经病3例. 中华肝脏病杂志,2012,9(20):707-708. ]9] 李晨,段学章,胡瑾华. 乙型肝炎肝硬化患者应用恩替卡韦分散片致周围神经病变1例. 肝脏,2012,17(2):148-149. [10] Yuan K,Guochun W,Huang Z,et al. Entecavir-associated myopathy:a case report and literature review. Muscle Nerve, 2014,49(4):610-614. [11] Brinkman K,ter Hofstede HJ,Burger DM,et al. Adverse effects of reverse transcriptase inhibitors:mitochondrial toxicity as common pathway. AIDS,1998,12(14):1735-1744. [12] Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology,2009,49 (5 Suppl.):S185-195. [13] Lange CM,Bojunga J,Hofmann WP et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology,2009,50(6): 2001-2006. [14] Lewis W,Day BJ,Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs:an integrated cellular perspective. Nat Rev Drug Discov,2003,2(10):812-822. [15] Mazzucco CE, Hamatake RK, Colonno RJ, et al. Entecavir for reatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition. Antimicrob Agents Chemoter, 2008, 52(2): 598-605. [16] 中华医学会感染病学分会肝衰竭与人工肝学组和肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南. 实用肝脏病杂志,2013,16(3):210-216. [17] Lim CY,Kowdley KV. Optimal duration of therapy in HBV-related cirrhosis. J Antimicrob Chemother,2007,60(1): 2-6. [18] Zuber M,Gause A. Peripheral neuropathy during interferon-alpha therapy in patients with cryoglobulinemia and hepatitis virus infection. J Rheumatol,1997,24(12):2488-2489. [19] Fung J,Lai CL,Yuen MF. LB80380: a promising new drug for the treatment of chronic hepatitis B. Expert Opin Investig Drugs,2008,17(10):1581-1588. [20] Yuen MF,Ahn SH,Lee KS,et al. Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir:results from a multicentre study. J Hepatol,2015,62(3):526-532. |